-

08:51:19 AM

THTX Stock News

THTX - Theratechnologies Inc.

03/14/23 6:42 PM

Nasdaq : THTX

conferencesclinical trial

Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

Data show that sudocetaxel zendusortide (TH1902) can induce tumor infiltrating lymphocytes and potentiate anti-PD-L1 immunotherapy in a melanoma mouse model Two other studies highlight activity of TH1902 in SORT1+ triple-negative and HER2+ breast cancers, as well as high expression of SORT1 in

RHEA-AI

neutral

03/07/23 6:00 AM

Nasdaq : THTX

Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the

RHEA-AI

neutral

02/28/23 7:30 AM

Nasdaq : THTX

earnings

Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022

Q4 2022 consolidated revenue growth of 14.2% to $21.4 million FY2022 revenue totaled $80.1 million or growth of ~15%, in line with guidance FY2023 operating plan to focus on achieving positive Adjusted EBITDA 1 by year end based on commercial business growth and tighter budget controls FY2023

RHEA-AI

neutral

02/28/23 6:30 AM

Nasdaq : THTX

Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management

Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December

RHEA-AI

neutral

02/22/23 5:30 PM

Nasdaq : THTX

Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV

Presentation at Conference on Retroviruses and Opportunistic Infections (CROI) demonstrates association between excess visceral abdominal fat (EVAF) reduction and decreased prevalence of metabolic syndrome with tesamorelin treatment Data provide further evidence of potential utility of tesamorelin

RHEA-AI

neutral

02/16/23 7:30 AM

Nasdaq : THTX

clinical trial

Theratechnologies Announces Path to Resume TH1902 Clinical Development

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the

RHEA-AI

neutral

02/14/23 5:00 PM

Nasdaq : THTX

earnings

Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and

RHEA-AI

neutral

01/04/23 7:45 AM

Nasdaq : THTX

Open Letter to Shareholders from CEO Paul Levesque

Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance FY2023 revenue guidance range set between $90 million and $95 million, ending the new year

RHEA-AI

positive

12/01/22 6:30 PM

Nasdaq : THTX

Theratechnologies Announces Update from Ongoing TH1902 Study

Theratechnologies Inc. (“Theratechnologies” or the

RHEA-AI

neutral

10/26/22 7:30 AM

Nasdaq : THTX

Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays

Poster for presentation at the 34 th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances understanding of SORT1 expression in healthy and tumor tissues Extensive dataset underscores potential of SORT1 as a new anticancer therapeutic target MONTREAL, Oct. 26, 2022 (GLOBE

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next